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INTRODUCTION 
Snake bite is an occupational hazard of farmers, plantation workers and 
others, resulting in tens of thousands of deaths each year.  Approximately 15% 
of the 3000 species of snakes found worldwide are considered to be dangerous 
to humans. There are about 216 species of snakes identifiable in India, of 
which 52 are known poisonous.  
The major families of snakes in India are Elapidae which includes 
common cobra ( Naja naja), king cobra and common krait (Bungarus 
caerulus), Viperidae includes Russell’s viper, saw scaled viper (Echis 
carinatus) and pit viper and Hydrophidae (the sea snakes).  
More than 2,00,000 snakebites are reported in the country annually and 
it is estimated that between 35000 and 50,000 people die of snakebite each 
year in India. Deaths typically occur in children, in the elderly, and in victims 
to whom antivenom is not given, is given after a delay, or is administered in 
insufficient quantities. Typically, victims are male and between 17 and 27 years 
of age. 98% of bites are on extremities, most often the hands or arms, and result 
from deliberate attempts to handle, harm, or kill the snake. Most bites occur 
between April and September, when snakes are active and humans are 
outdoors. 
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ASV is most prestigious and valued, its preparation involves catching or 
parking snakes, milking of snakes at laboratory, immunizing horses with 
venom. Hence ASV should be used only in an indicated case in proper doses to 
prevent crisis of its supply.  In India polyvalent ASV is available which 
contains antibody against cobra, Russell’s viper, common krait and saw-scaled 
viper. Many times it is administered in nonindicated cases. 
Total dose of Anti Snake Venom 
 The empirical total doses of ASV used in various centers in India are as 
follows (JAPI Vol 52 JAN 2004, Snake Venoms & Antivenoms: Critical Supply Issues, HS Bawaskar): 
 
1. For Russell’s Viper : 100 – 800 ml 
2. For Saw Scaled Viper : 20 – 450 ml 
3. For Krait   : 50 – 360 ml 
4. For Cobra   : 50 – 360 ml 
 
ASV neutralizes the circulating venom only and no amount of ASV will 
neutralize or combine with venom once the venom is attached or adsorbed to 
target organs i.e. platelets, RBCs, vascular endothelium, renal tubules, muscles 
and neuromuscular receptors. Early administration of ASV prevents the target 
organ damage. Half-life of ASV varies 26- 96 hours, whereas antigen (venom) 
may reappear in circulation as long as 130 hours. 
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Five lakh ASV vials are manufactured by the four institutes (Haffkine  
Institute, Mumbai, Serum institute, Pune, King Institute, Chennai & Central 
Research Institute, Kasauli). Exact total amount of venom injected by snake at 
the time of bite is unknown. However, the clinical features and outcomes are 
not as simple as predicted, because every bite does not result in complete 
envenomation. 
Features of Venom and Antivenom 
The approximate fatal doses of venom of the poisonous snakes are as 
follows: 
1. For Russell’s Viper  : 150 mg 
2. For Cobra    : 120 mg 
3. For Saw scaled Viper  : 80 mg 
4. For Krait    : 60 mg 
 
The approximate quantity of venom neutralised by 1ml of Polyvalent 
ASV is given below: 
1. For Russell`s Viper  : 0.60 mg 
2. For Cobra    : 0.60 mg 
3. For Saw Scaled Viper  : 0.45 mg 
4. For Krait    : 0.45 mg 
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However, ASV is the cornerstone in management of snakebite, even 
though the optimal dose, frequency and mode of administration and duration of 
therapy remain unclear. There are only a few trials from India, which address 
these questions. Accurate optimization of therapy may lead to a reduction in the 
dose. Though the use of anti-snake venom (ASV) has been in existence for 
many years, there is no universally accepted standard regarding the optimum 
dose of ASV, its frequency of administration and duration of therapy. 
 
Keeping all the above-mentioned issues in mind, this study was 
conducted to evaluate the optimal dose and use of ASV in In-patients admitted 
in IV Medical unit, Department of Medicine in Govt Rajaji Hospital, Madurai. 
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REVIEW OF LITERATURE 
VENOMOUS SNAKES OF SOUTH-EAST ASIA 
THE VENOM APPARATUS 
 Venomous snakes of medical importance have a pair of enlarged teeth, 
the fangs, at the front of their upper jaw. These fangs contain a venom channel 
(like a hypodermic needle) or groove, along which venom can be introduced 
deep into the tissues of their natural prey. If a human is bitten, venom is usually 
injected subcutaneously or intramuscularly. 
 
 
Venom apparatus of a saw-scaled viper 
 
Classification 
 
There are 2 important groups (families) of venomous snakes in South-
East Asia.  
 6
Elapidae have short permanently erect fangs. This family includes the 
cobras, king cobra, kraits, coral snakes and the sea snakes. The most important 
species, from a medical point of view, include the following: 
 
Cobra 
 
Cobras:                     N naja            Common Spectacled Indian cobra  
(Genus Naja)             N oxiana                North Indian or Oxus cobra  
                                   N kaouthia            Monocellate cobra  
                                   N philippinensis    Philippine cobra 
                                   N atra                    Chinese cobra  
Spitting cobras:        N siamensis  
                                   N sumatrana  
                                   N sputatrix  
King cobra:              Ophiophagus hannah 
 
Kraits:                       B caeruleus           Common krait  
(Genus Bungarus)      B candidus            Malayan krait  
                                   B multicinctus       Chinese krait  
                                   B fasciatus             Banded krait  
 
Sea snakes:             important genera include Enhydrina, Lapemis & Hydrophis 
r 
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Viperidae have long fangs, which are normally folded up against the 
upper jaw but, when the snake strikes, are erected. There are two subgroups, the                            
typical Vipers (Viperinae) and the Pit vipers (Crotalinae). The Crotalinae 
have a special sense organ, the pit organ, to detect their warm-blooded prey. 
This is situated between the nostril and the eye. Medically important species in 
South-East Asia are:Scaled V 
iper 
 
Typical vipers:    Daboia russelii                      Russell’s vipers  
                              Echis carinatus                      Saw-scaled or carpet vipers 
                   E sochureki 
 
Pit vipers:            Calloselasma rhodostoma     Malayan pit viper  
                               Hypnale hypnale                   hump-nosed viper 
 
 
 
Green pit vipers or bamboo vipers: (genus Trimeresurus) 
                             T albolabris                            White-lipped green pit viper 
                             T gramineus                           Indian bamboo viper 
                             T mucrosquamatus                 Chinese habu  
                             T purpureomaculatus             Mangrove pit viper 
                             T stejnegeri Chinese              Bamboo viper 
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Saw Scaled Viper Saw 
 
Russell’s Viper 
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Venomous snakes identification 
 
1. Pupil shape. The pupil of harmless snakes is round. Poisonous 
snakes have elliptical pupils. 
2. Pit. Poisonous snakes have a pit (hence the name “pit viper”) 
on each side of the head, about midway and slightly below the 
eye & nostril. The pit looks like a nostril & helps the snake 
locate warm-bodied food. Harmless snakes do not have pits. 
3. Scale arrangement. The underside scales of a venomous 
snake’s tail go all the way across in a single row from the anal 
plate. The very tip of the tail may have two scale rows. 
Nonpoisonous snakes have two rows of scales from the vent to 
the end of the tail.  
4. Head shape. Venomous snakes have a triangular (wide at the 
back and attached to a narrow neck) or “spade-shaped” head.  
5. Distinctive sound. Rattlesnakes will usually sound a warning 
rattle (a buzz or a dry, whirring sound) when approached.  
6. Tail. Cottonmouths and copper heads can be recognized by 
their bright yellow or greenish yellow tail. 
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Differences between Venomous and Nonvenomous Snakes 
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Composition of venom 
Snake venoms contain more than 20 different constituents, mainly 
proteins, including enzymes and polypeptide toxins.  
1. Procoagulant enzymes (Viperidae) that stimulate blood 
clotting but result in incoagulable blood. Eventually, and 
sometimes within 30 minutes of the bite, the levels of clotting 
factors have been so depleted (“consumption coagulopathy”) 
that the blood will not clot. 
2. Haemorrhagins (zinc metalloproteinases) damage the 
endothelial lining of blood vessel walls causing spontaneous 
systemic hemorrhage. 
3. Cytolytic or necrotic toxins – these proteolytic enzymes and 
phospholipases A  increase permeability resulting in local swelling. 
4. Hemolytic and myolytic phospholipases A2 - these enzymes 
damage cell membranes, endothelium, skeletal muscle, nerve 
and red blood cells. 
5. Pre-synaptic neurotoxins (Elapidae and some Viperidae) - 
these are phospholipases A2 that damage nerve endings, 
initially releasing acetylcholine transmitter, then interfering 
with release. 
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6. Post-synaptic neurotoxins (Elapidae) - these polypeptides 
compete with acetylcholine for receptors in the neuromuscular 
junction and lead to curare-like paralysis. 
Quantity of venom injected at a bite 
 
This is very variable, depending on the species and size of the snake, the 
mechanical efficiency of the bite, whether one or two fangs penetrated the skin 
and whether there were repeated strikes. 
About 50% of bites by Malayan pit vipers and Russell’s vipers, 30% 
of bites by cobras and 5-10% of bites by saw-scaled vipers do not result in 
any symptoms or signs of envenomation.  
Bites by small snakes should not be ignored or dismissed. They should 
be taken just as seriously as bites by large snakes of the same species. 
Incidence of snakebites 
 
India – More than 2,00,000 snakebite are reported annually and it is 
estimated that between 35000 and 50,000 people die of snakebite each year. 
How do snakebites happen? 
  
Most snakebite happen when the snake is trodden on, either in the dark 
or in undergrowth, by someone who is bare-footed or wearing only sandals. The 
snake may be picked up, unintentionally in a handful of foliage or intentionally 
by someone who is trying to show off. Some bites occur when the snake 
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(usually a krait) comes in to the home at night in search of its prey (other 
snakes, lizards, frogs, mice) and someone sleeping on the floor rolls over onto 
the snake in their sleep.  
Symptoms and Signs of Snake Bite 
When venom has not been injected 
 
This results from the fear of the consequences of a real venomous bite. 
Anxious people may over breathe so that they develop paraesthesia, stiffness or 
tetany of their hands and feet, dizziness, vasovagal shock.  
Local symptoms and signs in the bitten part 
 
• Local pain                                           
• Fang marks 
• Local bleeding 
• Bruising 
• Lymphangitis 
 
• Lymphadenitis 
• Necrosis  
• Blistering, Inflammation 
• Local infection, abscess formation 
However, bites by kraits and sea snakes may be virtually painless and 
may cause negligible local swelling. 
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Systemic symptoms and signs 
 
1. General: Nausea, vomiting, malaise, abdominal pain, weakness, 
drowsiness. 
 
2. Cardiovascular (Viperidae): Visual disturbances, dizziness, faintness, 
collapse, shock, hypotension, cardiac arrhythmias, pulmonary edema, 
conjunctival edema. 
3. Bleeding and clotting disorders (Viperidae):  
a. Bleeding from recent wounds (including fang marks, 
venepunctures etc) and from old partly-healed wounds. 
b. Spontaneous systemic bleeding – from gums, epistaxis, bleeding 
into the tears, haemoptysis, haematemesis, rectal bleeding or 
malaena, haematuria, vaginal bleeding, bleeding into the skin 
(petechiae, purpura, ecchymoses) and mucosae (e.g.) 
conjunctivae, intracranial hemorrhage. 
4. Neurological (Elapidae, Russell’s viper) Drowsiness, paraesthesiae, 
abnormalities of taste and smell, ptosis, external ophthalmoplegia, 
paralysis of facial muscles, aphonia, difficulty in swallowing secretions, 
respiratory and generalized flaccid paralysis. 
5. Skeletal muscle breakdown (Sea snakes, Russell’s viper) Generalized 
pain, stiffness and tenderness of muscles, trismus, myoglobinuria, 
hyperkalaemia, cardiac arrest, acute renal failure. 
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6. Renal (Viperidae, Sea snakes) Loin pain, haematuria, 
haemo/myoglobinuria, oliguria/anuria, uremia. 
7. Endocrine (acute pituitary/adrenal insufficiency) (Russell’s viper)   
a. Acute phase: shock, hypoglycemia  
b. Chronic phase (months to years): weakness, loss of secondary  sexual 
hair, amenorrhoea, testicular atrophy, hypothyroidism etc 
Long-term complications (sequelae) of snakebite 
 
Chronic ulceration, infection, osteomyelitis or arthritis may persist 
causing severe physical disability. Malignant transformation may occur in skin 
ulcers after a number of years. Chronic renal failure occurs after bilateral 
cortical necrosis (Russell’s viper bites) and chronic panhypopituitarism or 
diabetes insipidus after Russell’s viper bites. Chronic neurological deficit is 
seen in the few patients who survive intracranial hemorrhages (Viperidae). 
Management - First aid treatment 
 
First aid treatment is carried out immediately or very soon after the bite, 
before the patient reaches a dispensary or hospital. Unfortunately, most of the 
traditional, popular, available and affordable first aid methods have proved to 
be useless or even frankly dangerous. These methods include: 
a. Making local incisions at the site of the bite or in the bitten limb, 
b. Attempts to suck the venom out of the wound,  
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c. Tying tight bands (tourniquets) around the limb,  
d. Electric shock, topical application of chemicals, herbs or ice packs. 
Recommended first aid methods 
 
1. Reassure the victim who may be very anxious 
2. Immobilise the bitten limb with a splint or sling 
3. Consider pressure-immobilisation for some elapid bites 
4. Avoid any interference with the bite wound as this may introduce 
infection, increase absorption of the venom and increase local bleeding. 
Pressure immobilisation method. Ideally, an elasticated, crepe 
bandage, approximately 10 cm wide and at least 4.5 meters long should be 
used. The bandage is bound firmly around the entire bitten limb, starting 
distally around the fingers or toes and moving proximally, to include a rigid 
splint. The bandage is bound as tightly as for a sprained ankle, but not so tightly 
that the peripheral pulse is occluded or that a finger cannot easily be slipped 
between its layers. 
           
 
       
Pressure immobilisation method 
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Pressure immobilisation is recommended for bites by neurotoxic elapid 
snakes, including sea snakes. 
Early clues of envenomation 
 
1. Snake identified is a very dangerous one 
2. Rapid early extension of local swelling from the site of the bite 
3. Early tender enlargement of local lymph nodes 
4. Early systemic symptoms: hypotension, shock, nausea, vomiting, 
diarrhea, severe headache,  drowsiness or early ptosis/ophthalmoplegia 
5. Early spontaneous systemic bleeding 
6. Passage of dark brown urine 
7. Generalised pain, tenderness and stiffness of muscles and trismus 
Physical examination 
 
Examination of the bitten part 
The extent of swelling, lymph nodes and overlying ecchymoses and 
lymphangitic lines noted. Early signs of necrosis may include blistering, 
demarcated darkening or paleness of the skin, loss of sensation and a smell of 
putrefaction (rotting flesh). 
General examination 
Measure the blood pressure and heart rate. Thoroughly examine the 
gingival sulci, using a torch and tongue depressor, as these may show the 
earliest evidence of spontaneous systemic bleeding. Examine the nose for 
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epistaxis. Abdominal tenderness may suggest gastrointestinal or retroperitoneal 
bleeding. Loin pain and tenderness suggests acute renal ischaemia (Russell’s 
viper bites). Intracranial hemorrhage is suggested by lateralising neurological 
signs, asymmetrical pupils, convulsions or impaired consciousness. 
 
Neurotoxic envenoming 
 
 Ask the patient to look up and observe whether the upper lids retract 
fully. Test eye movement. Check the size and reaction of the pupils. 
 Ask the patient to open their mouth wide and protrude their tongue; early 
restriction in mouth opening may indicate trismus (sea snake envenoming) or 
more often paralysis of pterygoid muscles. 
  
 
 
Check other muscles innervated by the cranial nerves (facial muscles, 
tongue, gag reflex etc). The muscles flexing the neck may be paralysed, giving 
the “broken neck sign”. 
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Bulbar and respiratory paralysis 
 
Can the patient swallow or are secretions accumulating in the pharynx, 
an early sign of bulbar paralysis? Ask the patient to take deep breaths in and 
out. “Paradoxical respiration” indicates that the diaphragm is still contracting 
but that the intercostal muscles and accessory muscles of inspiration are 
paralysed. Use a peak flow meter, spirometer (FEV1 and FVC) or ask the 
patient to blow into the tube of a sphygmomanometer to record the maximum 
expiratory pressure (mmHg).  
Generalised rhabdomyolysis 
 
In victims of envenoming by sea snakes and Russell’s vipers, muscles, 
especially of the neck, trunk and proximal part of the limbs, may become tender 
and painful on active or passive movement and later may become paralysed. In 
sea snake bite, there is pseudotrismus that can be overcome by sustained 
pressure on the lower jaw. Myoglobinuria may be evident 3 hours after the bite. 
Signs, symptoms Cobra Krait Russell’s 
viper 
Saw scaled 
viper 
Other 
vipers 
Local pain/tissue 
damage Yes No Yes Yes Yes 
Neurotoxicity Yes Yes Yes! No No 
Vasculotoxicity No No Yes Yes Yes 
Renal problems No No Yes No Yes 
Neostigmine & 
Atropine Yes No? No? No No 
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Examination of pregnant women 
 
There will be concern about fetal distress (revealed by fetal bradycardia), 
vaginal bleeding and threatened abortion. Monitoring of uterine contractions 
and fetal heart rate is useful. Lactating women who have been bitten by snakes 
should be encouraged to continue breast-feeding. 
Investigations / laboratory tests 
20 minute whole blood clotting test (20WBCT) 
 
This is a very useful and informative bedside test that requires very little 
skill and only one piece of apparatus - a new, clean, dry, glass vessel (tube or 
bottle). 
1. Place a few mls of freshly sampled venous blood in a small glass vessel 
2. Leave undisturbed for 20 minutes at ambient temperature 
3. Tip the vessel once 
4. If the blood is still liquid (unclotted) and runs out, the patient has 
hypofibrinogenemia (“incoagulable blood”) as a result of venom-induced 
consumption coagulopathy 
5. In the South East Asian region, incoagulable blood is diagnostic of a 
viper bite and rules out an elapid bite  
6. If there is any doubt, repeat the test in duplicate, including a “control” 
(blood from a healthy person) 
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Other tests 
 
1. Hemoglobin concentration / haematocrit: a transient increase 
indicates haemoconcentration resulting from a generalised 
increase in capillary permeability (e.g. in Russell’s viper bite). 
More often, there is a decrease reflecting blood loss or 
intravascular haemolysis. 
2. Platelet count: this may be decreased in viper bites.  
3. White blood cell count: an early neutrophil leucocytosis is 
evidence of  systemic envenoming from any species.  
4. Blood film: fragmented red cells (“helmet cell”, schistocytes) are 
seen when there is microangiopathic haemolysis.  
5. Plasma / serum may be pinkish or brownish if there is gross 
haemoglobinaemia or myoglobinaemia.  
6. Biochemical abnormalities: Muscle enzymes (creatine kinase, 
aldolase etc) will be elevated if there is generalized muscle 
damage. Mild hepatic dysfunction is reflected in slight increases 
in aminotransferases. Bilirubin is elevated following massive 
extravasation of blood. Creatinine, urea or blood urea nitrogen 
levels are raised in renal failure. Early hyperkalaemia may be seen 
following extensive rhabdomyolysis in sea snake bites. 
Bicarbonate will be low in metabolic acidosis.  
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7. Arterial blood gases and pH may show evidence of respiratory 
failure (neurotoxic envenoming) and acidaemia (respiratory or 
metabolic acidosis). Arterial puncture is contraindicated in 
patients with haemostatic abnormalities.  
8. Desaturation: arterial oxygen desaturation can be assessed non-
invasively in patients with respiratory failure or shock using a 
pulse oximeter.  
9. Urine examination: the urine should be tested by dipsticks for 
blood/haemoglobin/myoglobin. Microscopy will confirm whether 
there are erythrocytes in the urine. Red cell casts indicate 
glomerular bleeding. Massive proteinuria is an early sign of the 
generalized increase in capillary permeability in Russell’s viper 
envenoming. 
Antivenom treatment 
 
Antivenom is the only specific antidote to snake venom. Antivenom is 
immunoglobulin (usually the enzyme refined F (ab) 2 fragment of IgG) purified 
from the serum or plasma of a horse or sheep that has been immunised with the 
venoms of one or more species of snake.  
Monovalent or monospecific antivenom neutralises the venom of only 
one species of snake. Polyvalent or polyspecific antivenom neutralises the 
venoms of several different species of snakes. For example, Haffkine, Kasauli, 
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Serum Institute of India and Bengal “polyvalent anti-snake venom serum” is 
raised in horses using the venoms of the four most important venomous snakes 
in India (Indian cobra, Naja naja; Indian krait, Bungarus caeruleus; Russell’s 
viper, Daboia russelii; saw-scaled viper, Echis carinatus).  
Antibodies raised against the venom of one species may have cross-
neutralising activity against other venoms, usually from closely related species. 
This is known as Para specific activity. 
Indications for antivenom 
 
Antivenom treatment is recommended if and when a patient with proven 
or suspected snake develops one or more of the following signs. 
Systemic envenoming 
 
1.  Haemostatic abnormalities: spontaneous systemic bleeding, 
coagulopathy or thrombocytopenia 
2. Neurotoxic signs: ptosis, external ophthalmoplegia, paralysis etc 
3. Cardiovascular abnormalities: hypotension, shock, cardiac 
arrhythmia, abnormal ECG 
4. Acute renal failure: oliguria/anuria, rising blood creatinine/ urea 
5. Haemoglobin-/myoglobin-uria: dark brown urine, urine dipsticks, 
other evidence of intravascular haemolysis or generalised 
rhabdomyolysis (muscle aches and pains, hyperkalaemia) 
6. Supporting laboratory evidence of systemic envenoming 
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Local envenoming 
 
1. Local swelling involving more than half of the bitten limb (in the 
absence of a tourniquet) & swelling after bites on the digits 
2. Rapid extension of swelling (e.g. beyond the wrist or ankle within a few 
hours of bites on the hands or feet) 
3. Development of an enlarged tender lymph node draining the bitten limb 
Antivenom treatment should be given as soon as it is indicated. It may 
reverse systemic envenoming even when this has persisted for several days or, 
in the case of haemostatic abnormalities, for two or more weeks. However, 
when there are signs of local envenoming, without systemic envenoming, 
antivenom will be effective only if it can be given within the first few hours 
after the bite. 
Administration of antivenom 
 
1. Adrenaline should always be kept ready.  
2. Antivenom should be given by the intravenous route whenever possible. 
Freeze-dried antivenoms are reconstituted, usually with 10 ml of sterile 
water for injection per ampoule. 2 methods of administration are recommended: 
(1) Intravenous “push” injection: reconstituted freeze-dried or liquid 
antivenom is given by slow intravenous injection (not more than 2 ml/minute).  
(2) Intravenous infusion: reconstituted freeze-dried or liquid antivenom is 
diluted in 250-500 ml of isotonic saline or 5% dextrose and is infused in 1 hour. 
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Local administration of antivenom at the bite site is not recommended. 
 
Subcutaneous injection of antivenom 
 
This should not be done as it is extremely painful, may increase 
intracompartmental pressure and has not been shown to be effective. 
Intramuscular injection of antivenom 
 
Disadvantages – poor bioavailability, haematoma formation and pain. 
Situations in which intramuscular administration might be considered: 
1. At a peripheral first aid station, before a patient with obvious 
envenoming is put in an ambulance for a journey to hospital that may 
last several hours; 
2. When intravenous access has proved impossible. 
The dose of antivenom should be divided between a number of sites in 
the upper anterolateral region of both thighs. A maximum of 5-10 ml should be 
given at each site by deep IM injection followed by massage to aid absorption. 
Antivenom should never be injected into the gluteal region (upper outer 
quadrant of the buttock) as absorption is exceptionally slow and unreliable and 
there is always the danger of sciatic nerve damage. 
Dose of antivenom 
 
Snakes inject the same dose of venom into children and adults. Children 
must therefore be given exactly the same dose of antivenom as adults. For Mild 
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envenomation 5 vials,  for Moderate envenomation - 10 vials and for Severe 
envenomation15-20 vials. 
Antivenom reactions 
 
A proportion of patients, usually more than 20%, develop a reaction 
either early (within a few hours) or late (5 days or more) after being given 
antivenom.  
1. Early anaphylactic reactions: usually within 10-180 minutes of starting 
antivenom, the patient begins to itch (often over the scalp) and develops 
urticaria, dry cough, fever, nausea, vomiting, abdominal colic, diarrhea, 
tachycardia, hypotension, bronchospasm and angio-oedema. 
2. Pyrogenic (endotoxin) reactions usually develop 1-2 hours after 
treatment. Symptoms include shaking chills (rigors), fever, 
vasodilatation and a fall in blood pressure. 
3. Late (serum sickness type) reactions develop 1-12 (mean 7) days after 
treatment. Clinical features include fever, nausea, vomiting, diarrhea, 
itching, recurrent urticaria, arthralgia, myalgia, lymphadenopathy, 
periarticular swellings, mononeuritis multiplex, proteinuria with immune 
complex nephritis and rarely encephalopathy.  
Treatment of early anaphylactic and pyrogenic antivenom reactions 
1. Antivenom administration must be temporarily suspended 
2. Adrenaline (0.1% solution, 1 in 1,000, 1 mg/ml)  
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After adrenaline, an antihistamine such as chlorpheniramine maleate, 
cimetidine or ranitidine should be given followed by intravenous 
hydrocortisone (adults 100 mg, children 2 mg/kg body weight). In pyrogenic 
reactions the patient must also be cooled physically and with antipyretics. 
Treatment of late (serum sickness) reactions 
A 5-day course of prednisolone should be given if patients fail to 
respond in 24-48 hours to a 5-day course of oral antihistamine.  
Prediction of antivenom reactions 
 
Skin “hypersensitivity” tests may reveal IgE mediated Type I 
hypersensitivity to horse or sheep proteins but do not predict the large majority 
of early (anaphylactic) or late (serum sickness type) antivenom reactions. 
Contraindications to antivenom 
 
There is no absolute contraindication to antivenom treatment. 
Prophylaxis in high risk patients for antivenom reactions 
High-risk patients may be pre-treated empirically with subcutaneous 
adrenaline, intravenous antihistamines (both anti-H1 and anti- H2) and 
corticosteroid. In asthmatic patients, prophylactic use of an inhaled adrenergic 
beta 2 agonist such as salbutamol may prevent bronchospasm. 
Observation of the response to antivenom 
 
If an adequate dose of appropriate antivenom has been administered, the 
following responses may be seen. 
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1. General: the patient feels better. Nausea, headache and generalised aches 
and pains may disappear very quickly.  
2. Spontaneous systemic bleeding usually stops within 15- 30 minutes. 
3. Blood coagulability (20WBCT) is usually restored in 3-9 hours. 
4. In shocked patients, blood pressure may increase within the first 30-60 
minutes and arrhythmias such as sinus bradycardia may resolve. 
5. Neurotoxic envenoming of the post-synaptic type (cobra bites) may 
begin to improve as early as 30 minutes after antivenom, but usually take 
several hours. Envenoming with presynaptic toxins (kraits and sea 
snakes) is unlikely to respond in this way.  
6. Active haemolysis and rhabdomyolysis may cease within a few hours 
and the urine returns to its normal colour. 
Recurrence of systemic envenoming 
In patients envenomed by vipers, signs of systemic envenoming may 
recur within 24-48 hours. This is attributable to: 
1. Continuing absorption of venom from the “depot” at the site of the bite, 
perhaps assisted by improved blood supply following correction of 
shock, hypovolaemia etc, after elimination of antivenom (range of 
elimination halflives: IgG 45 hrs; F (ab) 2 80-100 hrs; Fab 12-18 hrs); 
2. Redistribution of venom from the tissues into the vascular space, as the 
result of antivenom treatment. 
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Recurrent neurotoxic envenoming after treatment of cobra bite has also 
been described. 
Criteria for giving more antivenom 
 
1. Persistence or recurrence of blood incoagulability after 6 hr of bleeding 
2. Deteriorating neurotoxic or cardiovascular signs after 1-2 hr 
If the blood remains incoagulable (as measured by 20WBCT) six 
hours after the initial dose of antivenom, the same dose should be repeated. 
This is based on the observation that, if a large dose of antivenom (more than 
enough to neutralise the venom procoagulant enzymes) is given initially, the 
time taken for the liver to restore coagulable levels of fibrinogen and other 
clotting factors is 3-9 hours. 
In patients who continue to bleed briskly, the dose of antivenom 
should be repeated within 1-2 hours. 
In case of deteriorating neurotoxicity or cardiovascular signs, the 
initial dose of antivenom should be repeated after 1-2 hours, and full supportive 
treatment must be considered. 
Complications 
 
1. Neurotoxic envenoming with respiratory paralysis:  
Assisted ventilation. This has proved effective, and has been followed by 
complete recovery, even after being maintained for periods of more than one 
month. Anticholinesterases should always be tried. 
 30
Anticholinesterase (e.g. “Tensilon”/edrophonium) test 
 
Anticholinesterase drugs have a variable, but potentially very useful 
effect in patients with neurotoxic envenoming, especially those bitten by 
cobras. A trial of anticholinesterase (e.g. “Tensilon test”) should be performed 
in every patient with neurotoxic envenoming, as it would be in any patient with 
suspected myasthenia gravis. 
• Baseline observations 
• Give atropine intravenously 
• Give anticholinesterase drug 
• Observe effect 
• If positive, institute regular atropine and (long acting) anticholinesterase 
Atropine sulphate (adults 0.6 mg, children 50 µg/kg body weight) is 
given by intravenous injection (to prevent the undesirable muscarinic effects of 
acetylcholine such as increased secretions, sweating, bradycardia and colic) 
followed immediately by edrophonium chloride (adults 10 mg, children 0.25 
mg/kg body weight) given intravenously over 3 or 4 minutes. The patient is 
observed over the next 10-20 minutes for signs of improved neuromuscular 
transmission. Ptosis may disappear and ventilatory capacity (peak flow, FEV1 
or maximum expiratory pressure) may improve. 
If edrophonium chloride is not available, any other anticholinesterases 
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(neostigmine, distigmine, pyridostigmine, ambenomium) can be used for this 
assessment but a longer period of observation will be needed (up to 1 hour). 
Patients who respond convincingly can be maintained on a longer-acting 
anticholinesterase such as neostigmine methylsulphate combined with atropine. 
2. Hypotension and shock 
 
Causes of hypotension and shock 
 
Anaphylaxis                                Antivenom reaction 
Vasodilatation                             Respiratory failure 
Cardiotoxicity                             Acute pituitary / adrenal insufficiency 
Hypovolaemia                             Septicaemia 
 
Ideally, treatment with plasma expanders (colloids or crystalloid) should 
be controlled by observation of the central venous pressure. In patients with 
evidence of a generalised increase in capillary permeability, dopamine may be 
given by intravenous infusion (starting dose 2.5-5 µg/kg/minute). In victims of 
Russell’s viper bites, acute pituitary / adrenal insufficiency resulting from 
haemorrhagic infarction of the anterior pituitary may contribute to shock. 
Hydrocortisone is effective in these cases. 
3. Oliguria and renal failure 
 
Most, but not all, patients with acute renal failure are oliguric, defined as 
a urine output of less than 400 ml/day or less than 20 ml/hour. If the patient is 
hypovolaemic, indicated by supine or postural hypotension, empty neck veins, 
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sunken eyeballs, loss of skin turgor and dryness of mucosae, proceed as 
follows: 
(1) Establish intravenous access 
(2) Insert a urethral catheter 
(3) Determine the central venous pressure 
(4) Fluid challenge: an adult patient can be given two liters of isotonic saline 
over one hour or, until the jugular venous pressure/central venous pressure has 
risen to 8-10 cm above the sternal angle. The fluid challenge must be stopped 
immediately if pulmonary oedema develops. If the urine output does not 
improve, try furosemide challenge. 
(5) Furosemide (frusemide) challenge: 100 mg of furosemide is injected 
slowly (4-5 mg/minute). If this does not induce a urine output of 40 ml/hour, 
give a second dose of furosemide, 200 mg. If urine output does not improve, try 
mannitol challenge. 
(6) Mannitol challenge: 200 ml of 20% mannitol may be infused intravenously 
over 20 minutes. An improvement in urine output to more than 40 ml/hr or 
more than 1 liter/day is considered satisfactory. 
(7) Conservative management: If the urine output does not improve, despite 
these challenges, no further diuretics should be given and fluid intake should be 
restricted to a total of the previous day’s output plus “insensible losses” (500-
1000 ml/day). If possible, the patient should be referred to a renal unit. 
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(8) Biochemical monitoring: Serum potassium, urea, creatinine and, if 
possible, pH, bicarbonate, calcium and phosphate should be monitored. 
Emergency treatment of hyperkalaemia  
 
a. Give 10 ml of 10% calcium gluconate intravenously over 2 
minutes (with ECG monitoring if possible), repeated up to three 
times 
b. Give 50 ml of 50% dextrose with 10 units of soluble insulin 
intravenously 
c. Sodium bicarbonate (40 ml of 8.4%) by slow intravenous infusion 
and a beta 2 agonist aerosol by inhaler (e.g. salbutamol 5-10 mg) 
may also be used. These emergency treatments will control 
hyperkalaemia for 3-6 hours only. If the patient is hypotensive 
and profoundly acidotic (deep sighing “Kussmaul” respirations, 
very low plasma bicarbonate concentration or very low pH - 
<7.10), 40 ml of 8.4% sodium bicarbonate (1 mmol/ml) may be 
infused intravenously over 30 minutes. If this leads to circulatory 
improvement, the dose can be repeated. 
(9) Dialysis 
 
Prevention of renal damage in patients with myoglobinuria or  
 
haemoglobinuria: 
 
• correct hypovolaemia and maintain saline diuresis (if possible) 
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• correct severe acidosis with bicarbonate  
 
• give a single infusion of mannitol (200 ml of 20% solution over 20 minutes) 
 
Persisting renal dysfunction 
 
Patients with patchy cortical necrosis show delayed and partial recovery 
of renal function but those with diffuse cortical necrosis require regular 
maintenance dialysis and eventual renal transplantation. 
4. Haemostatic disturbances 
 
In exceptional circumstances, such as severe bleeding or imminent 
urgent surgery, once specific antivenom has been given to neutralise venom 
procoagulants and other antihaemostatic toxins, restoration of coagulability and 
platelet function can be accelerated by giving fresh frozen plasma, 
cryoprecipitate (fibrinogen, factor VIII), fresh whole blood or platelet 
concentrates. 
Heparin is ineffective against venom-induced thrombin and may cause  
bleeding on its own account. It should never be used in cases of snake bite. 
Antifibrinolytic agents are not effective and should not be used. 
5. Bacterial infections 
 
Infection at the time of the bite with organisms from the snake’s venom 
and buccal cavity is a problem. Interference with the wound (incisions made 
with an unsterilised razor blade/knife etc) creates a risk of secondary bacterial 
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infection and justifies the use of broad-spectrum antibiotics (e.g. amoxycillin or 
a cephalosporin plus a single dose of gentamicin plus metronidazole) together 
with a booster dose of tetanus toxoid. 
The bitten limb, which may be painful and swollen, should be nursed in 
the most comfortable position, preferably slightly elevated, to encourage 
reabsorption of edema fluid. Bullae may be large and tense but they should be 
aspirated only if they seem likely to rupture. 
6. Compartmental syndrome - features 
 
• Disproportionately severe pain 
• Weakness of intracompartmental muscles 
• Pain on passive stretching of intracompartmental muscles 
• Hypoaesthesia  
• Obvious tenseness of the compartment on palpation 
The most reliable test is to measure intracompartmental pressure directly 
through a cannula introduced into the compartment and connected to a pressure 
transducer or manometer. Intracompartmental pressures exceeding 40 mmHg 
may carry a risk of ischaemic necrosis (e.g. Volkmann’s ischaemia or anterior 
tibial compartment syndrome). However, fasciotomy should not be 
contemplated until haemostatic abnormalities have been corrected. 
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AIMS AND OBJECTIVES 
 
1. To assess the severity of snakebite envenomation.  
2. To assess the dose of anti-snake venom to treat snake bites cases 
effectively according to severity. 
3. To calculate the total requirement of ASV.  
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MATERIALS AND METHODS 
 
Setting  :  All patients of snakebite including suspected cases of snakebite 
who were admitted in IV Medical unit, Department of Medicine, GRH, 
Madurai.  
Collaborating Departments    : Department of Pathology  
       Madurai Medical College 
       Madurai.  
       Department of Biochemistry 
       Madurai Medical College  
       Madurai 
Design of the study     : Descriptive study 
Period of study      : 01.01.2005 – 31.12.2005  
Sample size         : 120 
Ethical committee approval  : Obtained  
Consent     : Informed consent was obtained  
Financial support     : Nil  
Conflict of interest    : Nil  
 
.  
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DEFINITION  
Symptoms and signs of envenomation 
 The symptoms and signs of snakebite envenomation were based on 
1. Local findings 
2. Systemic findings 
3. Laboratory abnormalities 
Local findings  
The local findings due to snakebite envenomation are the following: 
1. Puncture wounds or fang marks 
2. Pain 
3. Bleeding 
4. Soft tissue swelling confined to the bite site or extending beyond 
the bite site 
5. Regional lymphadenitis    
Systemic findings  
The systemic findings due to snakebite envenomation are the following:  
1. Nausea, vomiting 
2. Blurring of vision, ptosis, paraesthesia, fasciculations 
3. Evidence of bleeding 
4. Hypotension or shock 
5. Respiratory distress – single breath count < 20 
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Laboratory abnormalities 
 The laboratory findings due to snakebite envenomation are the following  
1. Prolongation of clotting time 
2. Prolongation of prothrombin time 
3. Decreased platelet count 
4. Decreased fibrinogen 
5. Increased fibrin degradation products 
Severity of envenomation  
 The severity of snake bite envenomation were based on the local 
findings, systemic findings and laboratory abnormalities and the were classified 
into 3 types namely 
1. Mild 
2. Moderate 
3. Severe  
Mild envenomation   
The features of mild envenomation include ( any one )  
1. Local findings – punture wounds, pain, soft tissue swelling 
confined to the bite site   
2. Systemic findings – None 
3. Laboratory abnormalities – clotting time 11 to 15 minutes 
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Moderate envenomation  
 The features of moderate envenomation include ( any one ) 
1. Local findings – soft tissue swelling extending beyond the bite site, 
regional lymphadenitis 
2. Systemic findings – nausea, vomiting, blurring of vision, ptosis, 
paraesthesia, fasciculations 
3. Laboratory abnormalities – clotting time 16 to 20 minutes 
Severe envenomation  
 The features of severe envenomation include ( any one ) 
1. Local findings – soft tissue swelling extending beyond the bite site, 
regional lymphadenitis 
2. Systemic findings – Evidence of bleeding, hypotension, shock, 
respiratory distress (single breath count < 20) 
3. Laboratory abnormalities – clotting time > 20 minutes 
Dose of anti-snake venom – Initial Dose 
1. Mild envenomation  : 5 vials 
2. Moderate envenomation : 10 vials 
3. Severe envenomation  : 15 vials  
If repeat dosing is needed, the same dose in each category should be 
repeated depending upon the severity of envenomation.  
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Selection and Details of Study subjects 
120 patients of snake bite with or without evidence of envenomation 
including suspected cases who were admitted in IV Medical unit, Department 
of Medicine, Govt Rajaji Hospital, during the period from 01.01.2005 – 
31.12.2005 were included in the study.  
Inclusion criteria  
All patients admitted as a case of snakebite in IV Medical unit were taken.  
Exclusion criteria  
1. Patients who were treated with anti-snake venom elsewhere 
2. Bleeding diathesis of any cause before snake bite 
The total number of cases with Snake bite screened were 158 Of which 
36 cases who had received Anti Snake Venom elsewhere and 2 patients with 
known history of Bleeding diathesis  were excluded from the study. After 
exclusion of these patients, the total number of patients who were taken into 
account for our study were 120.  
120 patients who were included in the study were divided into 4 groups 
each containing 30 patients. 
1. Patients with No envenomation were included in Group 1,  
2. Patients with Mild envenomation were included in Group 2,  
3. Patients with Moderate envenomation were included in Group 3  
4. Patients with Severe envenomation were included in Group 4  
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based on Local features, Systemic features and Lab abnormality– Clotting time 
as mentioned earlier. Whole blood clotting time was done to assess the severity 
of snakebite envenomation. 
In Group I, 20 patients were males and 10 patients were females. In 
Group II, 16 patients were males and 14 patients were females. In Group III, 20 
patients were males and 10 patients were females. In Group IV , 19 persons 
were males and 11 persons were females. A total number of 75 males and 45 
females were selected for the study.  
 Polyvalent ASV was used in the study. The patients were given ASV 
after a sensitivity test, diluted with 500ml of dextrose or saline given over 4 
hours. All patients were given IM tetanus toxoid. 
The end point of the study was normalisation of haematological or 
neurological parameters or death.  
. 
 
 
. 
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Snake bite cases screened  
(n=158) 
Cases selected for study 
(n=120) 
Cases excluded from study 
(n=38) 
Pts received ASV elsewhere    (n=36) 
 
Bleeding diathesis     (n=02) 
 
Group I (No 
envenomation) 
(n=30) 
Group II (Mild 
envenomation) 
(n=30) 
 
Group III (Mod 
envenomation) 
(n=30) 
 
Group IV  (Severe 
envenomation) 
(n=30) 
 
Screening of Cases – Flow chart 
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RESULTS 
The collected data was analysed using Epidemiological information 
package 2002 developed by Centre for Disease Control (CDC) Atlanta in 
Collaboration with WHO. CHI square test was used for test of significance. 
These data was compared with published literature. 
 In our study, 120 Snakebite patients were studied. 
 
STATISTICS 
A. Study Parameters 
Table 1 Total cases 
Group 1 Group 2 Group 3 Group 4 Total 
30 30 30 30 120 
 
 120 patients were included in the study and they were divided into 4 
groups each containing 30 patients. Patients with No envenomation were 
included in Group 1, Patients with Mild envenomation were included in Group 
2, Patients with Moderate envenomation were included in Group 3 and Patients 
with Severe envenomation were included in Group 4 based on Local features, 
Systemic features and Lab abnormalities. 
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Table 2 Age 
Group 1 Group 2 Group 3 Group 4 Age 
Group No. % No. % No. % No. % 
< 21 
21-30 
31-40 
41-50 
>50 
Total 
4 
6 
9 
10 
1 
30 
13.4 
20.0 
30.0 
33.3 
3.3 
100 
7 
8 
9 
6 
- 
30 
23.3 
26.7 
30.0 
20.0 
- 
100 
2 
16 
11 
1 
- 
30 
6.7 
53.3 
36.7 
3.3 
- 
100 
3 
10 
9 
7 
1 
30 
10.0 
33.3 
30.0 
23.4 
3.3 
100 
‘p’ value > 0.05 (Not significant) 
  
33.3% of Group 1 patients belong to 41-50 years of age, 30.0% of Group 
2 patients belong to 31-40 years of age, 53.3% of Group 3 patients belong to 
21-30 years of age and 33.3% of Group 4 patients belong to 21-30 years of age. 
3.3% of patients in Group1 and 4 were more than 50 years of age. In Group 2 
and 3, all the patients were below 50 years of age. 
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Table 3 Sex 
 
Group 1 Group 2 Group 3 Group 4 Total 
Sex 
No. % No. % No. % No. % No. % 
Males 
Females 
20 
10 
66.7 
33.3 
16 
14 
53.3 
46.7 
20 
10 
66.7 
33.3 
19 
11 
63.3 
36.7 
75 
45 
62.5 
37.5 
‘p’ value > 0.05 (Not significant) 
 
 In Group 1, 66.7% were males and 33.3% were females. In Group 2, 
53.3% were males and 46.7% were females. In Group 3, 66.7% were males and 
33.3% were females. In Group 4, 63.3% were males and 36.7% were females. 
Overall, 62.5% of the patients included in the study were males and 37.5% were 
females. 
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Table 4 Co morbid illness 
 Group 1 Group 2 Group 3 Group 4 
DM 1 1 1 0 
HT 1 1 1 0 
IHD 1 1 1 1 
COPD 1 1 1 0 
 
 Among the 120 study patients, 3 patients had Diabetes one each in 
Group 1, Group 2 and Group 3, 3 patients had Hypertension one each in Group 
1, Group 2 and Group 3, 3 patients had Chronic Obstructive Pulmonary Disease 
one each in Group 1, Group 2 and Group 3 and 4 patients had Ischemic Heart 
Disease one each in each Group.   
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Table 5 Site of bite 
Group 1 Group 2 Group 3 Group 4 Total Site of 
bite No. % No. % No. % No. % No. % 
Upper 
limb 
9 30.0 10 33.3 13 43.3 9 30.0 41 34.2 
Lower 
limb 
21 70.0 20 66.7 17 56.7 21 70.0 79 65.8 
 ‘p’ value > 0.05 (Not significant) 
  
In Group 1 and 4, 30% of the patients had bite in the upper limb and 
70% of the patients had bite in the lower limb. In Group 2, 33.3% of the 
patients had bite in the upper limb and 66.7% of the patients had bite in the 
lower limb. In Group3, 43.3% of the patients had bite in the upper limb and 
56.7% of the patients had bite in the lower limb. Among the 120 study patients, 
34.2% of the patients had bite in the upper limb and 65.8% of the patients had 
bite in the lower limb.  
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Table 6 Time delay 
< 6 hours > 6 hours 
Time Delay 
No. % No. % 
Group 1 30 100.0 0 0 
Group 2 27 90.0 3 10.0 
Group 3 22 73.3 8 26.7 
Group 4 20 66.7 10 33.3 
Total 99 82.5 21 17.5 
 
  
All the patients in Group 1 came to the hospital within 6 hours of 
snakebite for treatment even though they had no signs of envenomation. 90%, 
73.3% and 66.7% of the patients in Group 1,2 and 3 respectively came to the 
hospital within 6 hours after snakebite. 10% of the patients in Group 2, 26.7% 
of the patients in Group 3 and 33.3% of the patients in Group 4 came to the 
hospital after 6 hours of snakebite. Overall, 82.5% of the patients came to the 
hospital within 6 hours of snakebite. 
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Table 7 Local features 
Absent Not extending  One joint 
Extending beyond  
One joint Local Features 
No. % No. % No. % 
Group 1 30 100 0 0 0 0 
Group 2 0 0 30 100 0 0 
Group 3 0 0 0 0 30 100 
Group 4 5 16.7 0 0 25 83.3 
 
 All the patients in Group 1 had no local features of envenomation. All 
the patients in Group 2 had local features in the bitten area with or without 
lymphadenitis but not extending beyond one joint. Similarly all the patients in 
Group3 had local features in the bitten area but with extension of cellulitis 
beyond one joint. 16.7% of the Group 4 patients had no local features. 83.3% of 
the Group 4 patients had local features in the bitten area but with extension of 
cellulitis beyond one joint. 
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Table 8 Systemic features 
Absent Mild Severe 
Systemic Features 
No. % No. % No. % 
Group 1 30 100 0 0 0 0 
Group 2 30 0 0 0 0 0 
Group 3 28 93.3 2 6.7 0 0 
Group 4 20 66.7 4 13.3 6 20.0 
 
 
 All the patients in Group1 and 2 had no systemic features. 93.3% of the 
Group3 and 66.7% of the Group 4 patients had no systemic features. 6.7% of 
Group3 and 13.3% of the Group 4 patients had mild systemic features. And 
20% of the Group 4 patients had severe systemic features. 
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Table 9 Clotting time 
 
Clotting 
time <10 min 11 – 15 min   16 – 20 min >20 min S.D. 
Group 1 30 0 0 0 1.20 
Group 2 0 30 0 0 0.63 
Group 3 0 0 30 0 0.94 
Group 4 5 0 0 25 - 
% 29.2 25.0 25.0 20.8 - 
 
 
 All the patients in Group 1 and 5 patients in Group 4 had normal clotting 
time. All the patients in Group 2 had clotting time between 11 and 15 minutes. 
All the patients in Group 3 had clotting time between 16 and 20 minutes. And 
25 patients in Group 4 had clotting time more than 20 minutes. 
Among the 120 study patients, 29.2% had normal clotting time. 25% had 
clotting time between 11 and 15 minutes and another 25% had clotting time 
between 16 and 20 minutes. And the remaining 20.8% had clotting time more 
than 20 minutes.  
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Table 10 Toxicity 
Toxicity Absent Hemotoxicity Neurotoxicity 
Group 1 30 0 0 
Group 2 0 30 0 
Group 3 0 30 0 
Group 4 0 25 5 
Total  No 30 85 5 
Total  % 25.0 70.8 4.2 
  
 
No symptoms and signs of envenomation were noted in Group 1 
patients. All the patients in Group 2 and Group 3 had signs and symptoms of 
Haemotoxicity. In Group 4, Haemotoxicity was noted in 25 patients and 
Neurotoxicity was noted in 5 patients. Among the 120 study patients, 25% of 
the patients had No symptoms and signs of envenomation, 70.8% of the patients 
had signs and symptoms of Haemotoxicity and 4.2% had signs and symptoms 
of Neurotoxicity. 
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Table 11 ASV dose - Average 
ASV dose Nil 5 vials 10 vials 15 vials 20 vials 30 vials 
Average 
in Vials 
Average 
in ml  S.D  
Group 1 30 0 0 0 0 0 0 0 - 
Group 2 0 30 0 0 0 0 5 50 - 
Group 3 0 0 28 0 2 0 10.67 106.7 1.31 
Group 4 0 0 0 25 0 5 17.50 175.0 1.72 
‘p’ value > 0.05 (Not significant) 
 
 
ASV was not given for patients in Group 1 since they had no symptoms 
and signs of envenomation. All the patients in Group 2 were treated each with 5 
vials of ASV. 28 patients in Group 3 were treated each with 10 vials of ASV 
and 2 patients were treated each with 20 vials of ASV. 25 patients in Group 4 
were treated each with 15 vials of ASV and 5 patients were treated each with 30 
vials of ASV.  Average dose of ASV required were 5 vials (50ml) in Group 2, 
10.67 vials (106.7ml) in Group 3 and 17.5 vials (175ml) in Group 4. 
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Table 12 a  ASV dose – Average & Maximum 
 
ASV dose Average ASV given in ml Maximum ASV given in ml 
Group 1 - - 
Group 2 50.0 50 
Group 3 106.7 200 
Group 4 175.0 300 
 
Maximum dose of ASV given in Group 2, Group3 and Group 4 were 
50ml, 200ml and 300ml respectively. 
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Table 12 b Clotting Time normalization 
6 hours 12 hours Clotting time 
normalization No. % No. % 
Group 1 - - - - 
Group 2 30 100.0 0 0 
Group 3 28 93.3 2 6.7 
Group 4 25 75.0 0 0 
 
 
Clotting time was normalized in 6 hours in 100%, 93.3% and 75% of 
Group 2, 3 & 4 patients respectively. Clotting time was normalized in 12 hours 
in 6.7% of Group 3 and these patients required 20 additional vials of ASV. 
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Table 13 Adverse effects 
Present Absent 
Adverse effects 
No. % No. % 
Group 1 - - - - 
Group 2 8 (5 + 3) 26.7 22 73.3 
Group 3 12 (9 + 3) 40.0 18 60.0 
Group 4 18 (14 + 4) 60.0 12 40.0 
Total  38 (28 + 10) 42.2 52 57.8 
A proportion of patients develop Antivenom reactions namely Early 
anaphylactic reactions (within10-180 minutes), Pyrogenic reactions (after1-2 hours) 
and Late (serum sickness type) reactions (after 1-12 days).In our study, 26.7% of 
Group 2, 40% of Group 3 & 60%Group 4 developed adverse effects to ASV. Among 
the 90 patients who were treated with ASV, 38 patients (42.2%) developed adverse 
effects to ASV & 52 patients (57.8%) had no adverse effects to ASV.  
Among 8 patients who developed adverse effects to ASV in Group 2, 5 
patients developed Pyrogenic reactions and 3 patients developed Anaphylactic 
reactions. Among 12 patients who developed adverse effects to ASV in Group 
3,9patients developed Pyrogenic reactions and 3 patients developed Anaphylactic 
reactions. Among 18 patients who developed adverse effects to ASV in Group 4, 14 
patients developed Pyrogenic reactions & 4 patients developed Anaphylactic 
reactions. Totally, among 38 patients who developed adverse effects to ASV, 28 
patients developed Pyrogenic reactions and 10 patients developed Anaphylactic 
reactions. None of the patients developed Late reactions in our study. 
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Table 14 Complications 
Complications Nil Renal failure 
Compartmental 
syndrome 
Respiratory 
failure 
Group 1 - - - - 
Group 2 30 0 0 0 
Group 3 28 1 1 0 
Group 4 25 1 1 3 
% 92.3 2.2 2.2 3.3 
 
 
No complications were seen in Group 2 patients. Acute Renal failure 
was seen in 2 patients one each in Group 3 and Group 4. Similarly 
Compartmental syndrome was seen in 2 patients one each in Group 3 and 
Group 4. 3 patients in Group 4 developed Acute Respiratory failure. 
92.3% had no complications, 2.2% developed Acute renal failure which 
was managed by Haemodialysis, 2.2% developed Compartmental syndrome 
which was managed with fasciotomy and 3.3% developed Acute Respiratory 
failure which was managed with Mechanical ventilation.  
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Table 15 Outcome 
Outcome Recovery Death 
Group 1 - - 
Group 2 30 0 
Group 3 30 0 
Group 4 30 0 
 
 
All the patients in our study recovered and no death occurred. 
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DISCUSSION & COMPARATIVE ANALYSIS 
 All the patients admitted as a case of Snakebite in IV Medical unit were 
considered for the study and 120 patients were selected and divided into 4 
Groups based on the severity of envenomation. Severity was based on 
symptoms and signs in the form of Local features, Systemic features and Lab 
abnormalities. 
 Patients who were treated with anti-snake venom elsewhere and patients 
who had Bleeding diathesis of any cause before snakebite were excluded from 
the study.  
Careful history and physical examination was done for all patients. By 
history, clinical examination and Biochemical investigations, patients included 
in the study were grouped. 120 patients were included in the study and they 
were divided into 4 groups each containing 30 patients. Patients with No 
envenomation were included in Group 1, Patients with Mild envenomation 
were included in Group 2, Patients with Moderate envenomation were included 
in Group 3 and Patients with Severe envenomation were included in Group 4 
based on Local features, Systemic features and Lab abnormalities. 
  Urine analysis, Random Blood sugar, Blood urea, S.creatinine, Clotting 
time, Prothrombin time, Complete Hemogram and ECG were done for all the 
patients. Clotting time was repeated every 6 hours for the patients who had 
 61
symptoms and signs of envenomation i.e. Groups 2, 3 and 4. And for patients in 
Group 1, Clotting time was repeated every 2 hours. 
 The presence and absence of Adverse effects of ASV, Complications of 
envenomation were noted. Normalisation of Clotting time after ASV therapy 
was also noted. Total dose of ASV required in each group was calculated.  
COMPARATIVE ANALYSIS 
120 patients were included in our study and they were divided into 4 
groups each containing 30 patients. V Paul et al conducted study in 100 patients 
and they were divided into 2 groups each containing 50 patients. J 
Srimannarayana et al conducted study in 90 patients and they were divided into 
3 groups each containing 30 patients. 
 The majority of patients in the study group were in the age group of 21-
30 years. In V Paul et al study, majority of patients in the study group were in 
the age group of 30-50 years.  
62.5% of the patients in the study group were males and 37.5% were 
females in our study. In V Paul et al study, 75% were males and 25% were 
females.  
 In our study, 65.8% of bites occurred in lower limbs and 34.2% occurred 
in upper limbs. In V Paul et al study, 80% of bites occurred in lower limbs and 
20% occurred in upper limbs. 
 62
Overall, 82.5% of the patients came to the hospital within 6 hours of 
snakebite. 
16.7% of the Group 4 patients had no local features & 83.3% had local 
features in the bitten area but with extension of cellulitis beyond one joint. 
93.3% of the Group3 and 66.7% of the Group 4 patients had no systemic 
features. 6.7% of Group3 and 13.3% of the Group 4 patients had mild systemic 
features. And 20% of the Group 4 patients had severe systemic features. 
29.2% of the study patients had clotting time <10 minutes, 25% had 
clotting time 11-15 minutes, 25% had clotting time 16-20 minutes and 20.8% 
had clotting time >20 minutes. In V Paul et al study, the average clotting time 
on the day of admission was 23.9 minutes in high dose group and 21.4 minutes 
in low dose group. J Srimannarayana et al study showed clotting time 26.2 min, 
22.2 min and 25 min for Group 1, 2 and 3 respectively. The difference in 
clotting time may be due to the fact that 30 patients in our study had no 
envenomation and only Hemotoxic snakebite patients were included in J 
Srimannarayana et al study. 
 In our study, 70.8% of the patients had Haemotoxicity and 4.2% had 
Neurotoxicity. In V Paul et al study, 74% of the patients had Haemotoxicity, 
16% had Neurotoxicity and the remaining 10% had both. Only Hemotoxic 
snakebite patients were included in J Srimannarayana et al study. Hemotoxicity 
was almost similar when compared with V Paul et al study. 
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 Average dose of ASV required were 5 vials (50ml) in Group 2, 10.67 
vials (106.7ml) in Group 3 and 17.5 vials (175ml) in Group 4.In V Paul et al 
study, a fixed dose of 6 vials (60ml) and 12 vials (120ml) were used for Low 
dose group and High dose group respectively. In J Srimannarayana et al study, 
376 ml, 197.67 ml and 205.33 ml were given for Regimen I, II and III 
respectively. The reason for decreased quantity of ASV requirement in our 
study when compared with J Srimannarayana et al study is due to the fact that 
in our study, patients were grouped according to the severity of envenomation, 
which was not done in J Srimannarayana et al study. 
Maximum dose of ASV given in Group 2, Group3 and Group 4 were 
50ml, 200ml and 300ml respectively. 
Clotting time was normalized in 6 hours in 86.7% of patients and in 12 
hours in 6.7% of patients in our study. In J Srimannarayana et al study, time 
lapse for clotting time normalization was 20.67 hours, 16.55 hours and 13.4 
hours in Regimen I, II and III respectively. The bite to needle time in J 
Srimannarayana et al study was 17 hours, 24.14 hours and 12 hours in Regimen 
I, II and III respectively and this delayed arrival to the hospital could be the 
reason for delay in clotting time normalization.  
8 patients of Group 2, 12 patients of Group 3 and 18 patients of Group 4 
developed adverse effects to ASV.  Among the 90 patients who were treated 
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with ASV, 38 patients (42.2%) developed adverse effects to ASV and 52 
patients (57.8%) had no adverse effects to ASV. 
In our study, among the 90 patients who were treated with ASV, 92.3% 
had no complications, 2.2% developed Acute renal failure, 2.2% developed 
Compartmental syndrome and 3.3% developed Acute Respiratory failure. In V 
Paul et al study, 22% developed Acute Renal Failure and 2% developed Acute 
Respiratory Failure. In J Srimannarayana et al study, 52.2% developed Acute 
Renal Failure. Again the delayed arrival to the hospital may be the reason for 
increased incidence of Acute renal failure in J Srimannarayana et al study. 
All the patients in our study recovered and no death occurred. In V Paul 
et al study, mortality rate was 12% and in J Srimannarayana et al study, 
mortality rate was 22.2%. Delayed arrival to the hospital, lack of categorisation 
based on severity of envenomation and increased incidence of complications 
could be the reasons for increased mortality rate in V Paul et al study and in J 
Srimannarayana et al study. 
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CONCLUSION  
1. 62.5% of the patients were males and 37.5% were females. 
2. 65.8% of the patients had bite in the lower limb and 34.2% had bite 
in the upper limb. 
3. 82.5% of the patients came to the hospital within 6 hours of 
snakebite and 17.5% came to the hospital after 6 hours. 
4. 29.2% of the patients had clotting time <10 minutes, 25% had 
clotting time 11-15 minutes, 25% had clotting time 16-20 minutes 
and 20.8% had clotting time >20 minutes.  
5. 70.8% of the patients had Haemotoxicity and 4.2% had 
Neurotoxicity.  
6. Average dose of ASV required were 5 vials (50ml) in Group 2, 
10.67 vials (106.7ml) in Group 3 & 17.5 vials (175ml) in Group 4.  
7. Maximum dose of ASV given in Group 2, Group 3 and Group 4 
were 50ml, 200ml and 300ml respectively. 
8. Clotting time was normalized in 6 hours in 86.7% of patients and in 
12 hours in 6.7% of patients. 
9. 38 patients (42.2%) developed adverse effects to ASV and 52 
patients (57.8%) had no adverse effects to ASV. 
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10. 92.3% had no complications, 2.2% developed Acute Renal failure, 
2.2% developed Compartmental syndrome and 3.3% developed 
Acute Respiratory failure. 
11. All the patients in our study recovered and no death occurred. 
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SUMMARY 
             The study “Snake Bite Envenomation and Anti Snake Venom 
– A Descriptive study” was done in 120 patients of Snakebite admitted in IV 
Medical unit, Department of Medicine, Government Rajaji Hospital, Madurai. 
120 patients were divided into 4 groups each containing 30 patients. Patients 
with No envenomation were included in Group 1, Patients with Mild 
envenomation were included in Group 2, Patients with Moderate envenomation 
were included in Group 3 and Patients with Severe envenomation were 
included in Group 4 based on Local features, Systemic features and Lab 
abnormalities. 
  
The patients who satisfied the inclusion criteria underwent various 
investigations like Urine analysis, Random Blood sugar, Blood urea, 
S.creatinine, Clotting time, Prothrombin time, Complete Hemogram and ECG 
were done for all the patients. Clotting time was repeated every 6 hours for the 
patients who had symptoms and signs of envenomation i.e. Groups 2, 3 and 4. 
And for patients in Group 1, Clotting time was repeated every 2 hours. 
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The severity of snake bite envenomation, the dose of anti-snake venom 
to treat snakebites cases effectively according to severity and the total 
requirement of ASV were assessed. 
Majority of patients in the study group were in the age group of 21-30 
years. Most of the patients were males. 
Most of the patients had snakebite in the lower limbs. Haemotoxic 
snakebite was more common than neurotoxic snakebite.  
The average dose and the maximum dose of Anti Snake Venom 
increased as the severity of Snake bite envenomation increased. 
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 GLOSSARY 
AE   - Adverse Effects 
ASV   - Anti Snake Venom 
COPD   - Chronic Obstructive Pulmonary Disease 
CT   - Clotting Time 
CTN   - Clotting Time Normalisation 
DM   - Diabetes Mellitus 
GRH   - Government Rajaji Hospital 
HT   - Hypertension 
IHD   - Ischemic Heart Disease 
LA   - Lab Abnormalities  
LF   - Local Features 
P   - Pregnancy 
SF   - Systemic Features 
TD   - Time Delay 
 
 
 
 
 
 PROFORMA 
1. Name                                              2. Age                     3. Sex 
 
4. Address 
 
5. Time delay before hospitalization 
(a) Less than 6 hours          (b) More than 6 hours 
 
6. Pre-hospital treatment with ASV 
 
7. Snakes brought for identification (type of snake) 
 
8. Site of bite 
 
9. Bite wound incised or not 
 
10. Clinical features 
(a) Local features 
 
      (b) Systemic features 
 
11. Nature of Envenomation 
(a) Hemotoxic      (b) Neurotoxic        (c) Both 
 
12. Vital signs 
      (a) Pulse rate                                      (b) Respiratory rate 
      (c) Single breath count                      (d) Blood pressure 
 
13. Co-morbid status:                              14. Pregnancy 
 
15. Cardio vascular status                       16. Respiratory status 
 
17. Neurological status                             18. Renal status 
 
19. Laboratory studies 
a. Clotting time : 
D1                 D2                D3                  D4                  D5 
b. Urine analysis :    Blood urea : 
 
 c. Serum creatinine :                              Blood Sugar  
 
d. Serum Potassium    ECG : 
 
e. Prothrombin time :     
 
f. Complete Hemogram : 
Hb            TC                                 DC 
            ESR                                                PCV  
            RBC count                                      Platelet count 
            BT                                                   CT 
            Peripheral smear 
               RBC`s 
               WBC`s 
               Platelets 
 
20. ASV dose required 
 
21. Adverse reactions to ASV 
 
22. Time lapse for CT normalization 
 
23. Recurrent Coagulopathy 
 
24. Complications 
     (a) ARF                                              (b) Respiratory failure 
 
     (c) Compartment syndrome             (d) DIC 
  
     (e) Others 
 
25. Duration of stay 
 
26. Outcome     27. Others 
 
  
  
  
MASTER CHART 
 
Sl.No AGE SEX GROUP DM HT IHD COPD P SITE TD LF SF LA CT TOXICITY ASV CTN AE COMPL OUTCOME 
1 46 1 1 2 2 2 2   1 1 1 1 1 1 1         1 
2 20 2 1 2 2 2 2 2 1 1 1 1 1 1 1         1 
3 28 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
4 32 2 1 2 2 2 2 2 2 1 1 1 1 1 1         1 
5 41 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
6 38 2 1 2 2 2 2 2 2 1 1 1 1 1 1         1 
7 65 1 1 1 2 1 2   2 1 1 1 1 1 1         1 
8 39 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
9 49 2 1 2 2 2 1 2 2 1 1 1 1 1 1         1 
10 21 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
11 18 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
12 31 2 1 2 2 2 2 2 1 1 1 1 1 1 1         1 
13 40 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
14 37 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
15 38 2 1 2 2 2 2 2 2 1 1 1 1 1 1         1 
16 46 1 1 2 1 2 2   2 1 1 1 1 1 1         1 
17 20 2 1 2 2 2 2 2 1 1 1 1 1 1 1         1 
18 24 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
19 34 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
20 39 2 1 2 2 2 2 2 2 1 1 1 1 1 1         1 
21 30 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
22 41 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
23 44 2 1 2 2 2 2 2 1 1 1 1 1 1 1         1 
24 29 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
25 48 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
26 41 1 1 2 2 2 2   2 1 1 1 1 1 1         1 
27 45 2 1 2 2 2 2 2 1 1 1 1 1 1 1         1 
28 29 1 1 2 2 2 2   1 1 1 1 1 1 1         1 
29 20 1 1 2 2 2 2   1 1 1 1 1 1 1         1 
30 43 1 1 2 2 2 2   1 1 1 1 1 1 1         1 
 
  
 
 
Sl.No AGE SEX GROUP DM HT IHD COPD P SITE TD LF SF LA CT TOXICITY ASV CTN AE COMPL OUTCOME 
31 40 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
32 35 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
33 25 2 2 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 1 1 
34 35 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
35 20 2 2 2 2 2 2 2 2 1 2 1 2 2 2 1 1 1 1 1 
36 23 2 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 2 1 1 
37 29 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
38 33 2 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 1 1 1 
39 32 1 2 2 2 2 2  1 1 2 1 2 2 2 1 1 1 1 1 
40 30 2 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 1 1 1 
41 46 2 2 1 2 1 2 2 2 1 2 1 2 2 2 1 1 2 1 1 
42 37 1 2 2 2 2 2 2 2 2 2 1 2 2 2 1 1 1 1 1 
43 21 2 2 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 1 1 
44 18 1 2 2 2 2 2  1 1 2 1 2 2 2 1 1 2 1 1 
45 19 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
46 41 2 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 2 1 1 
47 25 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 1 1 1 
48 27 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 1 1 1 
49 44 2 2 2 1 2 2 2 2 1 2 1 2 2 2 1 1 2 1 1 
50 42 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 1 2 1 1 
51 32 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
52 35 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
53 40 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 1 1 1 1 
54 19 1 2 2 2 2 2  1 1 2 1 2 2 2 1 1 2 1 1 
55 17 2 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 2 1 1 
56 18 1 2 2 2 2 2  1 1 2 1 2 2 2 1 1 2 1 1 
57 20 1 2 2 2 2 2  1 1 2 1 2 2 2 1 1 2 1 1 
58 48 2 2 2 2 2 1 2 2 1 2 1 2 2 2 1 1 2 1 1 
59 23 2 2 2 2 2 2 2 2 1 2 1 2 2 2 1 1 2 1 1 
60 45 1 2 2 2 2 2  2 1 2 1 2 2 2 1 1 2 1 1 
 
  
 
 
Sl.No AGE SEX GROUP DM HT IHD COPD P SITE TD LF SF LA CT TOXICITY ASV CTN AE COMPL OUTCOME 
61 23 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 2 1 1 
62 28 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 1 1 1 
63 42 1 3 1 2 2 2  2 1 3 1 2 3 2 2 1 2 1 1 
64 18 2 3 2 2 2 2 2 2 1 3 1 2 3 2 2 1 1 1 1 
65 31 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 1 1 1 
66 36 1 3 2 2 2 2  1 1 3 1 2 3 2 2 1 1 1 1 
67 25 2 3 2 2 2 2 2 2 1 3 1 2 3 2 2 1 2 1 1 
68 27 1 3 2 2 2 2  1 2 3 2 2 3 2 4 2 2 1 1 
69 29 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 2 1 1 
70 30 2 3 2 2 2 2 2 1 1 3 1 2 3 2 2 1 1 2 1 
71 32 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 1 1 1 
72 19 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 1 1 1 
73 40 2 3 2 2 2 1 2 2 1 3 1 2 3 2 2 1 2 1 1 
74 27 1 3 2 2 2 2  1 2 3 1 2 3 2 2 1 2 1 1 
75 33 2 3 2 2 2 2 2 2 2 3 1 2 3 2 2 1 2 1 1 
76 40 2 3 2 1 2 2 2 2 1 3 1 2 3 2 2 1 2 1 1 
77 29 1 3 2 2 2 2  1 2 3 2 2 3 2 4 2 2 1 1 
78 36 1 3 2 2 2 2  1 1 3 1 2 3 2 2 1 1 1 1 
79 29 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 1 3 1 
80 26 2 3 2 2 2 2 2 1 1 3 1 2 3 2 2 1 2 1 1 
81 38 1 3 2 2 2 2  1 2 3 1 2 3 2 2 1 2 1 1 
82 30 2 3 2 2 2 2 2 2 1 3 1 2 3 2 2 1 2 1 1 
83 29 1 3 2 2 2 2  1 1 3 1 2 3 2 2 1 2 1 1 
84 40 1 3 2 2 1 2  1 1 3 1 2 3 2 2 1 1 1 1 
85 27 1 3 2 2 2 2  1 2 3 1 2 3 2 2 1 1 1 1 
86 29 2 3 2 2 2 2 2 2 2 3 1 2 3 2 2 1 1 1 1 
87 31 1 3 2 2 2 2  1 2 3 1 2 3 2 2 1 2 1 1 
88 28 2 3 2 2 2 2 2 2 1 3 1 2 3 2 2 1 2 1 1 
89 34 2 3 2 2 2 2 2 1 1 3 1 2 3 2 2 1 2 1 1 
90 29 1 3 2 2 2 2  2 1 3 1 2 3 2 2 1 2 1 1 
 
  
 
 
Sl.No AGE SEX GROUP DM HT IHD COPD P SITE TD LF SF LA CT TOXICITY ASV CTN AE COMPL OUTCOME 
91 23 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 2 1 1 
92 26 1 4 2 2 2 2  2 1 3 2 2 4 2 3 1 1 1 1 
93 39 2 4 2 2 2 2 2 2 1 3 1 2 4 2 3 1 1 1 1 
94 49 1 4 2 2 2 2  2 1 3 3 2 4 2 3 1 1 1 1 
95 47 2 4 2 2 2 2 2 1 2 1 3 1 1 3 5  2 4 1 
96 31 2 4 2 2 2 2 2 2 1 3 2 2 4 2 3 1 1 1 1 
97 42 1 4 2 2 2 2  1 1 3 1 2 4 2 3 1 2 1 1 
98 29 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 1 1 1 
99 20 2 4 2 2 2 2 2 2 2 3 2 2 4 2 3 1 1 1 1 
100 30 1 4 2 2 2 2  2 1 3 3 2 4 2 3 1 1 1 1 
101 38 1 4 2 2 2 2  1 1 3 3 2 4 2 3 1 2 1 1 
102 46 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 1 1 1 
103 19 1 4 2 2 2 2  1 2 1 1 1 1 3 5  2 1 1 
104 51 2 4 2 2 2 2 2 2 2 3 1 2 4 2 3 1 2 1 1 
105 50 1 4 2 2 1 2  1 1 3 1 2 4 2 3 1 1 1 1 
106 39 2 4 2 2 2 2 2 2 1 3 1 2 4 2 3 1 2 2 1 
107 27 1 4 2 2 2 2  2 2 3 1 2 4 2 3 1 1 1 1 
108 35 1 4 2 2 2 2  2 1 3 2 2 4 2 3 1 1 1 1 
109 40 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 1 1 1 
110 25 2 4 2 2 2 2 2 2 1 3 1 2 4 2 3 1 2 3 1 
111 48 1 4 2 2 2 2  1 2 1 1 1 1 3 5  2 1 1 
112 30 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 1 1 1 
113 38 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 2 1 1 
114 17 1 4 2 2 2 2  1 1 1 3 1 1 3 5  1 4 1 
115 30 1 4 2 2 2 2  2 1 3 1 2 4 2 3 1 1 1 1 
116 35 2 4 2 2 2 2 2 2 2 3 1 2 4 2 3 1 1 1 1 
117 50 2 4 2 2 2 2 2 1 2 1 3 1 1 3 5  1 4 1 
118 26 1 4 2 2 2 2  2 2 3 1 2 4 2 3 1 2 1 1 
119 30 1 4 2 2 2 2  1 1 3 1 2 4 2 3 1 2 1 1 
120 38 2 4 2 2 2 2 2 2 2 3 1 2 4 2 3 1 1 1 1 
 
  
 
 
 
Sex:     1-Male, 2-Female                                             Group: 1-No envenomation, 2-Mild, 3-Moderate, 4-Severe                                               
 
DM:     1-Present, 2-Absent                                          HT: 1-Present, 2-Absent 
 
IHD:    1-Present, 2-Absent                                          COPD: 1-Present, 2-Absent 
 
Pregnancy:   1- Non pregnant                                       Site of bite: 1-Upper limb, 2-Lower limb 
 
Time delay:  1<6 hours, 2 >6 hours                              Local features: 1-Absent 
 2-Cellulitis not extending one joint,  
                                                                                                               3-Cellulitis extending beyond one joint 
 
Systemic features:  1-Absent,                                       Lab abnormalities: 1-Absent, 2-Present 
                               2-Mild, 3-Severe                            
 
Clotting time: 1 < 10 min, 1-11 to 15 min,    
                       3-16 to 20 min, 4 > 20 min                    Toxicity:   1-Hemo, 2-Neuro 
 
ASV: 1-5 vials, 2-10 vials, 3-15 vials,  
         4-20 vials, 5-30 vials             CT normalisation:   1-6 hours, 2-12 hours                   
 
Adverse effects: 1-Present, 2-Absent                 Complications:       1-Nil, 2- Renal failure,                  
                 3-Compartmental syndrome,   
Outcome: 1-Recovery, 2-Death             4-Respiratory failure    
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Graph 4 - Site of Snakebite
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Graph 5 - Time Delay
<6 hours >6 hours
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Graph 6 - Local Features
Absent Not extending one joint Extending beyond one joint
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Graph 7 -Systemic Features
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Graph 8 - Clotting Time
<10 min 11-15 min 16-20 min >20 min
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Graph 9 - Toxicity
Absent Hemotoxicity Neurotoxicity
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Graph 12 - Clotting time normalisation
6 hours 12 hours
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Graph 13b Adverse Effects
Pyrogenic reactions Anaphylactic reactions Late reactions
 
 
 
 0 0 0 0
30
0 0 0
28
1 1 0
25
1 1 3
0
5
10
15
20
25
30
Group 1 Group 2 Group 3 Group 4
Graph 14 - Complications
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